EWING, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
SAN FRANCISCO — The sumatriptan 3-mg subcutaneous auto-injector (Zembrace SymTouch, Promius Pharma) approved by the US Food and Drug Administration (FDA) for acute treatment of episodic migraine, with ...
Please provide your email address to receive an email when new articles are posted on . The FDA has accepted Eisai and Biogen’s biologics license application for a subcutaneous autoinjector weekly ...
The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results